No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
By Lori Solomon HealthDay Reporter
WEDNESDAY, Jan. 22, 2025 -- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online Jan. 16 in Thyroid.
Sarah M. Baxter, from Queen’s University Belfast in Northern Ireland, and colleagues investigated if GLP-1 RA use compared to use of dipeptidyl peptidase-4 inhibitors (DPP-4is) was associated with thyroid cancer risk in patients with type 2 diabetes. The analysis included 98,147 GLP-1 RA users and approximately 2.49 million DPP-4i users, with a median follow-up ranging from 1.8 to 3.0 years.
The researchers found that GLP-1 RA use was not associated with an increased risk for thyroid cancer (pooled weighted hazard ratio, 0.81; 95 percent confidence interval, 0.59 to 1.12) compared with use of DPP-4i. Among GLP-1 RA ever-users, there was no increased risk in thyroid cancer with an increasing cumulative dose of GLP-1 RA.
"In this large multisite study, utilizing data from six population-based databases, we found no evidence that GLP-1 RA use is associated with an increased risk of thyroid cancer with follow-up ranging from 1.8 to 3.0 years, providing some reassurance to patients and clinicians about the short-term safety of these drugs," the authors write. "Nevertheless, evidence was insufficient to rule out excess risk with long-term use, due to the short follow-up."
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Diabetes Risk Commonly Clustered Within Households
TUESDAY, Aug. 19, 2025 -- Diabetes risk is commonly clustered within households, according to a study scheduled to be presented at the annual meeting of the European Association...
PFAS Exposure Linked to Teen Weight Regain After Bariatric Surgery
TUESDAY, Aug. 19, 2025 -- For adolescents, exposure to perfluoroalkyl and polyfluoroalkyl substances (PFAS) is associated with weight regain after bariatric surgery, according to...
Saliva Insulin Can Differentiate Hyperinsulinemia in Normoglycemic People
MONDAY, Aug. 18, 2025 -- Saliva insulin can differentiate between normal and hyperinsulinemic responses among normoglycemic adults with different body mass index (BMI) classes...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.